You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 141 No. 1, January 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  This Month in Archives of Dermatology
 This Article
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

This Month in Archives of Dermatology

Arch Dermatol. 2005;141:11.

Treatment and Prophylaxis of Seborrheic Dermatitis of the Scalp With Antipityrosporal 1% Ciclopirox Shampoo

Seborrheic dermatitis is a common disorder with a chronic course of remissions and relapses. Because of the etiologic relationship of seborrheic dermatitis with the yeast Malassezia furfur, topical antifungals have proved useful in the treatment and prophylaxis of this condition. In this multicenter, randomized, double-blind, vehicle-controlled study, ciclopirox shampoo was effective in treating seborrheic dermatitis and preventing relapse of seborrheic dermatitis, thus offering patients a useful alternative to existing antipityrosporal therapies.

(SEE ARTICLE)


Members of the National Psoriasis Foundation

Psoriasis is a common, chronic disease that affects 4.5 million US patients. The National Psoriasis Foundation (NPF) serves as a patient advocacy group, representing those affected by psoriasis and providing information about the condition. In this study, Nijsten et al used random-digit dialing to identify and interview patients with psoriasis from the general US population. Randomly selected NPF members were also interviewed. Members of the NPF were older, more affluent, and more likely to report extensive disease than patients from the general population. Members were also less dissatisfied with their therapy and had a greater awareness of treatment options available to them. Only 1% of patients with psoriasis were aware of the NPF, and the significant gaps in most patients’ knowledge may impede them from obtaining effective psoriasis therapy.

(SEE ARTICLE)


Prevalence of Neurofibromatosis 1 in German Children at Elementary School Enrollment

Neurofibromatosis 1 (NF1) is an autosomal dominant neurocutaneous condition characterized by multiple café au lait macules, intertriginous freckling, and neurofibromas. Cerebral and spinal tumors, skeletal dysplasias, ophthalmologic abnormalities, and learning disabilities also commonly characterize this disease. Early diagnosis is essential for optimal management of this condition. By age 6 years, most children with NF1 can be identified using standard National Institutes of Health criteria. In this study, Lammert et al report a prevalence of 1:2635 for NF1 among 6-year-olds entering elementary school, clearly confirming that this is one of the most common autosomal dominant diseases among humans.

(SEE ARTICLE)


Necrolytic Acral Erythema

Necrolytic acral erythema (NAE) is a rare marker for hepatitis C disease, typically presenting as well-defined, tender, dusky, erythematous plaques on the dorsal surface of the feet that are unresponsive to topical steroids. Complete remission of this condition has been reported with parenteral interferon therapy with or without the addition of ribavirin. In this observation, Abdallah et al report that oral zinc administration alone resulted in disease remission in a patient with NAE, despite her normal plasma zinc level.


Well-defined, dusky, erythematous plaques are apparent on the dorsal surface of the feet.


(SEE ARTICLE)


Treatment of Diffuse Basal Cell Carcinomas and Basaloid Follicular Hamartomas in Nevoid Basal Cell Carcinoma Syndrome by Wide-Area 5-Aminolevulinic Acid Photodynamic Therapy

The nevoid basal cell carcinoma syndrome (BCC) is an autosomal dominant disorder characterized by multiple congenital abnormalities, increased risk of medulloblastoma, and the early development of BCCs. Topical 5-aminolevulinic acid photodynamic therapy is a relatively new treatment modality effective for localized BCCs. In this case series, Oseroff et al demonstrate that using this treatment over large body surface areas produced 85% to 98% clearance of lesions with minimal morbidity and rapid healing. Cosmetic outcomes were also reported as excellent, and the treatment effect was shown to be quite durable, with 1 patient being essentially carcinoma free for 6 years in the treated areas.

(SEE ARTICLE)

SECTION EDITOR: ROBIN L. TRAVERS, MD



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.